全基因组的CRISPR查揭示了一种由PKA驱动的抗性机制,用于预防口腔癌,可以通过与NSAIDs结合利用这种抗性机制
Thomas S Hoang1, Farhoud Faraji2, Amaya N Mendez-Molina1
1University of California, San Diego La Jolla, California United States.
Cancer prevention research (Philadelphia, Pa.)
|December 19, 2025
概括
甲胺和NSAID在预防头癌方面表现有前途. 结合这些药物协同抑制癌症生长并防止病变的进展,提供了一个新的化疗预防策略.
科学领域:
- 在瘤学瘤学.
- 预防癌症 预防癌症
- 药物发现 药物发现 药物发现
背景情况:
- 头部和部状细胞癌 (HNSCC) 患病率高,存活率差.
- 癌前病变的延迟诊断有助于HNSCC的不良结果.
- 甲胺显示出对HNSCC化学预防的潜力.
研究的目的:
- 在HNSCC中识别对美特福明的耐药性途径.
- 调查甲胺与其他HNSCC化疗预防药物的协同作用.
- 探索PKA和前列腺素E2信号传递在甲福林耐药性中的作用.
主要方法:
- 在用甲胺治疗的HNSCC细胞中进行全基因组CRISPR/Cas9选.
- 评估PKA激活和抑制的情况.
- 评估前列腺素E2 (PGE2) 自克林循环的参与.
- 使用甲福明,PKA抑制剂和COX2抑制剂 (NSAIDs) 的联合治疗研究.
- 使用口腔致癌模型的体内研究.
主要成果:
- 确定了PKA信号激活作为一种关键的甲福林耐药性途径.
- 甲胺治疗通过PGE2自环激活HNSCC细胞中的PKA信号.
- 抑制PKA与甲胺相结合,协同抑制了HNSCC生长.
- 使用NSAIDs的COX2抑制阻断了甲福林诱导的PKA激活.
- 甲福明和NSAIDs的组合协同抑制了HNSCC细胞生长,并防止了口服前恶性病变的进展.
结论:
- 在HNSCC中由甲胺诱导的PKA激活是由PGE2自环介导的.
- 将甲福明与PKA抑制剂或NSAIDs结合使用,显示出协同作用的抗癌效应.
- 甲胺和NSAID联合治疗是HNSCC化疗预防的有希望的策略.
- 这种组合可以防止口腔前恶性病变的进展到侵袭性癌症.
更多相关视频
07:52In Vivo CRISPR/Cas9 Screening to Simultaneously Evaluate Gene Function in Mouse Skin and Oral Cavity
Published on: November 2, 2020
6.9K
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
11.1K
相关概念视频
02:46Genetic Screens
5.5K
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
5.5K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
554
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
554
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K